Mineralocorticoid Receptor Antagonists
"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
| Descriptor ID |
D000451
|
| MeSH Number(s) |
D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
|
| Concept/Terms |
Mineralocorticoid Receptor Antagonists- Mineralocorticoid Receptor Antagonists
- Antagonists, Mineralocorticoid Receptor
- Receptor Antagonists, Mineralocorticoid
- Mineralocorticoid Antagonists
- Antagonists, Mineralocorticoid
- Aldosterone Receptor Antagonists
- Antagonists, Aldosterone Receptor
- Receptor Antagonists, Aldosterone
|
Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".
This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
Agarwal R, Verma A, Georgianos PI. Diuretics in patients with chronic kidney disease. Nat Rev Nephrol. 2025 Apr; 21(4):264-278.
-
Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, Kiernan MS, Kapur NK, Testani JM. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. J Card Fail. 2024 Nov; 30(11):1522-1526.
-
Schwann AN, Jaffe LM, Givertz MM, Wood KL, Engelman DT. Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery. Ann Thorac Surg. 2024 10; 118(4):792-800.
-
Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022 10 11; 43(38):3781-3791.
-
Brinkley DM, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021 12; 40(12):1605-1613.
-
Verma A, Patel AB. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. Trends Endocrinol Metab. 2021 05; 32(5):261-263.
-
Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 07; 131(7):837-841.
-
Khazanie P, Hammill BG, Patel CB, Kiernan MS, Cooper LB, Arnold SV, Fendler TJ, Spertus JA, Curtis LH, Hernandez AF. Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. J Card Fail. 2016 Sep; 22(9):672-9.
-
Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, Robertson D, Shibao CA, Biaggioni I. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. Hypertension. 2016 Feb; 67(2):424-9.
-
Hassan M, Qureshi W, Sroujieh LS, Albashaireh D, BouMalham S, Liroff M, Amjad W, Khalid F, Hadid H, Alirhayim Z. Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014 Sep; 15(3):278-85.